Illumina, Inc. vs Iris Energy Limited — how do they compare? Illumina, Inc. trades at $190.08 (market cap $27.94B), while Iris Energy Limited trades at $41.98 (market cap $14.37B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Iris Energy Limited nearer its low. Which is the better fit depends on your goals.
| ILMN | IREN | |
|---|---|---|
Market Cap | $27.94B | $14.37B |
Sector | Health | Energy |
52-Week High | $194.33 | $76.41 |
52-Week Low | $91.00 | $15.40 |
Enterprise Value | $29.33B | $16.12B |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
IREN trades at $40.20, up 19.57% in 24 hours but remains volatile amid a broader AI infrastructure stock sell-off. The stock shows a bearish technical signal with support at $31 and resistance at $36. Fundamentally, revenue grew to $501M in 2025 with a 20.88% net income margin, but recent quarters missed EPS expectations. The company is transitioning from Bitcoin mining to AI cloud services, with significant capital investment driving negative cash flow from investing activities.
Wall Street maintains a bullish stance with a $79.11 consensus price target and 71% buy ratings, citing IREN's AI infrastructure potential. However, execution risks, competitive pressures from Meta and peers, and recent earnings misses pose significant challenges. The stock's high valuation multiples (P/E 43.66) require flawless growth execution to justify current levels.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →